Price T Rowe Associates Inc Spring Works Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,110,462 shares of SWTX stock, worth $155 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,110,462
Previous 2,776,570
48.04%
Holding current value
$155 Million
Previous $101 Million
99.63%
% of portfolio
0.02%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding SWTX
# of Institutions
234Shares Held
67.7MCall Options Held
546KPut Options Held
29.4K-
Vanguard Group Inc Valley Forge, PA6.53MShares$246 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.44MShares$205 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.48MShares$131 Million5.66% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$129 Million8.76% of portfolio
-
Marshall Wace, LLP London, X02.97MShares$112 Million0.23% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.35B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...